{"success":true,"data":{"pressRelease":{"id":"59515","rtpr_id":"nNFC6kNWd4","ticker":"ENBIX","exchange":"","all_tickers":["ENBIX"],"title":"CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026","author":"Newsfile Corp","published_at":"2026-06-09T23:32:08.409Z","article_body":"Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon\nBiomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (\"Entheon\" or the\n\"Company\") wishes to correct the effective date of the appointment of Adam\nEmes as a director of the Company as stated in the Company's news release\ndated June 9, 2026. The appointment of Mr. Emes to the Company's Board of\nDirectors is effective June 9, 2026, not April 3, 2025 as previously stated.\nAll other information contained in the news release dated June 9, 2026 remains\nunchanged.\n\nAbout Entheon Biomedical Corp.\nEntheon is a biotechnology research and development company interested in\ntreating addiction and substance use disorders.\n\nOn Behalf of the Board of Directors,\nTimothy Ko, CEO and Director\n\nFor more information, please contact the Company at:\nEntheon Biomedical Corp.\nTimothy Ko, CEO\n1 (604) 562-3932\ntimothy@entheonbiomedical.com\nhttps://entheonbiomedical.com\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/300836","article_body_html":"","raw_payload":{"data":{"id":"nNFC6kNWd4","title":"CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026","author":"Newsfile Corp","ticker":"ENBIX","created":"2026-06-09T23:32:08.409Z","tickers":["ENBIX"],"exchange":"","article_body":"Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Entheon\nBiomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (\"Entheon\" or the\n\"Company\") wishes to correct the effective date of the appointment of Adam\nEmes as a director of the Company as stated in the Company's news release\ndated June 9, 2026. The appointment of Mr. Emes to the Company's Board of\nDirectors is effective June 9, 2026, not April 3, 2025 as previously stated.\nAll other information contained in the news release dated June 9, 2026 remains\nunchanged.\n\nAbout Entheon Biomedical Corp.\nEntheon is a biotechnology research and development company interested in\ntreating addiction and substance use disorders.\n\nOn Behalf of the Board of Directors,\nTimothy Ko, CEO and Director\n\nFor more information, please contact the Company at:\nEntheon Biomedical Corp.\nTimothy Ko, CEO\n1 (604) 562-3932\ntimothy@entheonbiomedical.com\nhttps://entheonbiomedical.com\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/300836"},"type":"article","timestamp":"2026-06-09T23:32:08.467188877Z","server_sent_at_ms":1781047928467},"received_at":"2026-06-09T23:32:08.537Z","source_url":"https://www.newsfilecorp.com/release/300836"},"analysis":{"id":"48941","press_release_id":"59515","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Entheon Biomedical issued a correction to its June 9 press release regarding the appointment of Adam Emes to its Board of Directors.\n\nThe correction clarifies that the appointment is effective June 9, 2026, rather than the previously stated date of April 3, 2025.\n\nAll other information in the original release remains unchanged, making this a purely administrative fix with no new strategic implications.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Administrative date correction for board appointment -- low signal."},"keyFigures":{},"quotedText":"The appointment of Mr. Emes to the Company's Board of Directors is effective June 9, 2026, not April 3, 2025 as previously stated.","namedEntities":{"people":[{"name":"Adam Emes","role":"Director"},{"name":"Timothy Ko","role":"CEO and Director"}],"products":[],"companies":[{"name":"Entheon Biomedical Corp.","ticker":"ENBIX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a minor administrative correction to the effective date of a board appointment. The appointment itself was already announced; only the date was wrong. No new strategic or operational information is disclosed."},"tickerRelevance":{"others":[],"primary":"ENBIX"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"administrative_correction","issuerAuthored":true}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Entheon Biomedical issued a correction to its June 9 press release regarding the appointment of Adam Emes to its Board of Directors.\n\nThe correction clarifies that the appointment is effective June 9, 2026, rather than the previously stated date of April 3, 2025.\n\nAll other information in the original release remains unchanged, making this a purely administrative fix with no new strategic implications.","key_figures":{},"named_entities":{"people":[{"name":"Adam Emes","role":"Director"},{"name":"Timothy Ko","role":"CEO and Director"}],"products":[],"companies":[{"name":"Entheon Biomedical Corp.","ticker":"ENBIX"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-09T23:32:16.658Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"administrative_correction","issuerAuthored":true}},"durationMs":8110,"modelName":"george-droid-qwen-72b"}}